Agios Pharmaceuticals Inc’s recent filing unveils that its Officer Goff Brian acquired Company’s shares for reported $0.41 million on Aug 08 ’25. In the deal valued at $37.06 per share,11,085 shares were bought.
Then, Scadden David sold 1,400 shares, generating $56,000 in total proceeds. Upon selling the shares at $40.00, the Director now owns 17,603 shares.
Before that, Gheuens Sarah sold 11,914 shares. Agios Pharmaceuticals Inc shares valued at $452,601 were divested by the Chief Medical Officer at a price of $37.99 per share. As a result of the transaction, Gheuens Sarah now holds 61,271 shares, worth roughly $2.15 million.
H.C. Wainwright initiated its Agios Pharmaceuticals Inc [AGIO] rating to a Buy in a research note published on February 24, 2025; the price target was $58. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in mid October with a ‘”a Sector outperform”‘ rating. Leerink Partners revised its rating on September 27, 2024. It rated AGIO as “a Market perform” which previously was an “an Outperform”.
Price Performance Review of AGIO
On Monday, Agios Pharmaceuticals Inc [NASDAQ:AGIO] saw its stock fall -1.90% to $35.08. Over the last five days, the stock has lost -2.99%. Agios Pharmaceuticals Inc shares have fallen nearly -17.59% since the year began. Nevertheless, the stocks have risen 6.76% over the past one year. While a 52-week high of $62.58 was reached on 07/23/25, a 52-week low of $23.42 was recorded on 04/09/25.
Levels Of Support And Resistance For AGIO Stock
The 24-hour chart illustrates a support level at 34.57, which if violated will result in even more drops to 34.07. On the upside, there is a resistance level at 35.72. A further resistance level may holdings at 36.37.
How much short interest is there in Agios Pharmaceuticals Inc?
A steep rise in short interest was recorded in Agios Pharmaceuticals Inc stocks on 2025-07-15, dropping by -0.14 million shares to a total of 4.18 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 4.32 million shares. There was a decline of -3.46%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on February 08, 2024 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating.
